220 related articles for article (PubMed ID: 19999133)
1. [Clinical efficacy of tolterodine for patients with overactive bladder after insufficient efficacy by monotherapy with alpha1-adrenoceptor antagonist].
Tsujimura A; Takao T; Uchida K; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Hirai T; Kiuchi H; Miyagawa Y; Takahashi T; Kojimaan Y; Okuyama A
Nihon Hinyokika Gakkai Zasshi; 2009 Nov; 100(7):686-92. PubMed ID: 19999133
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
Höfner K; Burkart M; Jacob G; Jonas U
World J Urol; 2010 Jun; 28(3):353-7. PubMed ID: 19997921
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
4. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
5. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
6. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.
Chapple CR; Herschorn S; Abrams P; Wang JT; Brodsky M; Guan Z
BJU Int; 2010 Nov; 106(9):1332-8. PubMed ID: 20497416
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia.
Höfner K; Burkart M; Jacob G; Jonas U
World J Urol; 2007 Dec; 25(6):627-33. PubMed ID: 17906864
[TBL] [Abstract][Full Text] [Related]
9. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
Wang YY; Shi GW; He JY; Zhang YB
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
[TBL] [Abstract][Full Text] [Related]
11. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.
Herschorn S; Heesakkers J; Castro-Diaz D; Wang JT; Brodsky M; Guan Z;
Curr Med Res Opin; 2008 Dec; 24(12):3513-21. PubMed ID: 19032133
[TBL] [Abstract][Full Text] [Related]
12. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
13. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
15. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.
Chung DE; Te AE; Staskin DR; Kaplan SA
Urology; 2010 May; 75(5):1144-8. PubMed ID: 20206978
[TBL] [Abstract][Full Text] [Related]
17. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
